Mielóma multiplex: vizsgálatok itt: Kína

In Kína 203 Also abroad 703

203 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

3. fázisTaking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
Guangzhou, Hangzhou, Jinan, Kunming, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
Életkor
18 év and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
1. fázisNot yet taking people in Kína
BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma
Where
Beijing
Életkor
18 év to 75 év
People
20
Run by
Liping Dou
See details and how to joinNCT07927842
Korai 1. fázisTaking people
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Where
Tianjin
Életkor
18 év to 75 év
People
18
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07322159
No phaseCsak meghívásos
Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
Where
Shanghai
People
40
Run by
RenJi Hospital
See details and how to joinNCT07833046
2. fázisNot yet taking people in Kína
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Where
Beijing
Életkor
18 év to 75 év
People
64
Run by
Excyte Biopharma Ltd
See details and how to joinNCT07695740
1. fázisTaking people
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Where
Kunming
Életkor
18 év and over
People
24
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07239323
2. fázisTaking people
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Beijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Xi'an
Életkor
18 év and over
People
510 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00
4. fázisTaking people
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Where
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
Életkor
18 év and over
People
295 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00
3. fázisTaking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xiamen, Xi'an, Zhengzhou
Életkor
18 év and over
People
1590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
3. fázisTaking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou, Wuhan, Xi'an
Életkor
18 év and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
1. fázisTaking people
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
Where
Shanghai
Életkor
18 év and over
People
122
Run by
Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT07914556
1. fázisNot yet taking people in Kína
Universal CAR-T Cells Targeting Multiple Myeloma
Where
Shenzhen
Életkor
18 év to 80 év
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT06006741
1/2. fázisNot yet taking people in Kína
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Where
Shenzhen
Életkor
18 év to 80 év
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT06429150
1. fázisNot yet taking people in Kína
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Where
Shenzhen
Életkor
18 év to 80 év
People
10
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT06435910
3. fázisNot yet taking people in Kína
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Where
Tianjin
Életkor
18 év and over
People
320
Run by
Keymed Biosciences Co.Ltd
See details and how to joinNCT07910903
1/2. fázisNot yet taking people in Kína
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Where
Shenzhen
Életkor
18 év to 80 év
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03271632
3. fázisTaking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Beijing, Changsha, Chongqing, Deyang, Guangzhou, Hangzhou, Kunming, Linhai, Liuzhou, Luoyang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Ürümqi, Wenzhou, Wuhan, Wuxi, Xiamen, Xi'an, Zhengzhou
Életkor
18 év and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
1/2. fázisTaking people
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Where
Beijing, Changsha, Guangzhou, Shenyang
Életkor
18 év and over
People
226 worldwide
Run by
AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00
4. fázisTaking people
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
Where
Nanjing
Életkor
18 év to 70 év
People
200
Run by
Chen Lijuan
See details and how to joinNCT07907211
2. fázisNot yet taking people in Kína
QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
Where
Tianjin
Életkor
18 év and over
People
55
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07903636
3. fázisTaking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
Életkor
18 év and over
People
1060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
2. fázisTaking people
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Where
Tianjin
Életkor
18 év to 70 év
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07106684
2. fázisTaking people
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Where
Tianjin
Életkor
18 év to 70 év
People
30
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07106710
2. fázisTaking people
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Where
Tianjin
Életkor
18 év to 75 év
People
60
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07106736
1/2. fázisTaking people
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Where
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
Életkor
18 év and over
People
246 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00